Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Dupilumab's Real-World impact on COPD over 3 years

NCT ID NCT07380711

Recruiting now Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Feb 02, 2026 · Last updated May 10, 2026 · Updated 11 times

Summary

This study follows about 500 adults with uncontrolled COPD who are taking dupilumab as part of their regular care. Researchers will collect data over 36 months to understand patient characteristics, safety, and how the drug affects symptoms and flare-ups. The goal is to learn more about dupilumab's long-term effects in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 2500001

    RECRUITING

    Pessac, 33604, France

  • Investigational Site Number : 2500002

    RECRUITING

    Montpellier, 34090, France

  • Investigational Site Number : 2500009

    RECRUITING

    Colmar, 68024, France

  • Investigational Site Number : 2500010

    RECRUITING

    Vantoux, 57070, France

  • Investigational Site Number : 2500017

    RECRUITING

    Paris, 400026, France

  • Investigational Site Number : 2500020

    RECRUITING

    Le Chesnay, 78157, France

  • Investigational Site Number : 2500021

    RECRUITING

    Aix-en-Provence, 13616, France

  • Investigational Site Number : 2500022

    RECRUITING

    Juan-les-Pins, 06600, France

  • Investigational Site Number : 2500024

    RECRUITING

    Marseille, 13003, France

  • Investigational Site Number : 2500026

    RECRUITING

    Nîmes, 30029, France

  • Investigational Site Number : 2500028

    RECRUITING

    Toulouse, 31059, France

  • Investigational Site Number : 2500029

    RECRUITING

    Toulouse, 31076, France

  • Investigational Site Number : 2500031

    RECRUITING

    Contamine-sur-Arve, 74130, France

  • Investigational Site Number : 2500033

    RECRUITING

    Lyon, 69008, France

  • Investigational Site Number : 2500034

    RECRUITING

    Pierre-Bénite, 69495, France

  • Investigational Site Number : 2500035

    RECRUITING

    Villeurbanne, 69100, France

  • Investigational Site Number : 2500038

    RECRUITING

    Libourne, 33500, France

  • Investigational Site Number : 2500040

    RECRUITING

    Niort, 79021, France

  • Investigational Site Number : 2500043

    RECRUITING

    Blois, 41016, France

  • Investigational Site Number : 2500044

    RECRUITING

    Brest, 29200, France

  • Investigational Site Number : 2500047

    RECRUITING

    Morlaix, 29600, France

  • Investigational Site Number : 2500048

    RECRUITING

    Saint-Pierre, 97448, France

Conditions

Explore the condition pages connected to this study.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)